Factors Associated with Fatality during the Intensive Phase of Anti-Tuberculosis Treatment
Rodrigo Sanz, Teresa (Sociedad Española de Neumología y Cirugía Torácica. Fundación Respira)
Casals, Martí (Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública)
Caminero, J. A. (Sociedad Española de Neumología y Cirugía Torácica. Fundación Respira)
García García, J. M. (Sociedad Española de Neumología y Cirugía Torácica. Fundación Respira)
Jiménez Fuentes, M. A. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Medina, J. F. (Sociedad Española de Neumología y Cirugía Torácica. Fundación Respira)
Millet, Joan-Pau (Sociedad Española de Neumología y Cirugía Torácica. Fundación Respira)
Ruiz Manzano, J.. (Sociedad Española de Neumología y Cirugía Torácica. Fundación Respira)
Caylà, Joan A.. (Sociedad Española de Neumología y Cirugía Torácica. Fundación Respira)

Date:	2016
Abstract:	Objective: To determine the case-fatality rate (CFR) at the end of the intensive phase of tuberculosis (TB) treatment, and factors associated with fatality. Methods: TB patients diagnosed between 2006 and 2013 were followed-up during treatment. We computed the CFR at the end of the intensive phase of TB treatment, and the incidence of death per 100 person-days (pd) of follow-up. We performed survival analysis using the Kaplan-Meier method and Cox regression, and calculate hazard ratios (HR) and 95% confidence intervals (CI). Results: A total of 5,182 patients were included, of whom 180 (3. 5%) died; 87 of these deaths (48. 3%) occurred during the intensive phase of treatment, with a CFR of 1. 7%. The incidence of death was 0. 028/100 pd. The following factors were associated with death during the intensive phase: being >50 years (HR = 36. 9;CI:4. 8-283. 4); being retired (HR = 2. 4;CI:1. 1-5. 1); having visited the emergency department (HR = 3. 1;CI:1. 2-7. 7); HIV infection (HR = 3. 4;CI:1. 6-7. 2); initial standard treatment with 3 drugs (HR = 2. 0;CI:1. 2-3. 3) or non-standard treatments (HR = 2. 68;CI:1. 36-5. 25); comprehension difficulties (HR = 2. 8;CI:1. 3-6. 1); and smear-positive sputum (HR = 2. 3-CI:1. 0-4. 8). Conclusion: There is a non-negligible CFR during the intensive phase of TB, whose reduction should be prioritised. The CFR could be a useful indicator for evaluating TB programs.
Note:	Ajuda rebuda: Sociedad Española de Pneumología y Cirugía Torácica (207/2011)
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Tuberculosi ; Tractament
Published in:	PloS one, Vol. 11 Núm. 8 (August 2016) , ISSN 1932-6203

DOI: 10.1371/journal.pone.0159925
PMID: 27487189

12 p, 638.6 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Research articles
Articles > Published articles